Salvatore B, Caprio M G, Fonti R, D'Amico D, Fraioli F, Salvatore M, Pace L
Consiglio Nazionale delle Ricerche-Istituto di Biostrutture e Bioimmagini, Napoli, Italy.
Dipartimento ad attività integrate di Diagnostica Morfologica e Funzionale, Radioterapia, Medicina Legale. Università degli Studi di Napoli Federico II, Italy.
Transl Med UniSa. 2014 Dec 19;11:34-8. eCollection 2015 Jan-Apr.
To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant.
3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value < 0.05 was considered significant.
(18)FDG PET/CT was positive in head district in 130/3502 (3,7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0,6%), soft tissue (55/158; 35%) and other sites (7/158; 4,4%). According to each group, patients were positive in the head district in 1.0% for Gastrointestinal Cancer (7/690), 3.0 % for Genitourinary Cancer (3/101), 3.7 % for Haemathologic Cancer (59/1590), 2.7 % for Gynaecologic Cancer (3/112), 7.8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 7.4% for Sarcoma (2/27), 11.6% for Unknown Primary Tumour (14/121).
Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour.
评估从大腿上部至颅顶进行常规的2-脱氧-2-[(18)F]氟-D-葡萄糖PET/CT（(18)FDG PET/CT）扫描是否具有临床相关性。
对3502例（1634例女性；平均年龄60±16岁）连续接受(18)FDG PET/CT检查的患者进行回顾性分析。根据原发性恶性肿瘤将患者分为10组。采用卡方分析评估比例之间的差异。p值<0.05被认为具有统计学意义。
在3502例患者中，130例（3.7%）患者的头部区域(18)FDG PET/CT呈阳性。在所有患者中，PET/CT检查前病变均未知。PET/CT在这130例患者中显示出158处脑部/头部摄取阳性。158处病变位于：脑（43/158；27%）、骨（52/158；33%）、淋巴结（1/158；0.6%）、软组织（55/158；35%）和其他部位（7/158；4.4%）。根据每组情况，胃肠道癌患者头部区域阳性率为1.0%（7/690），泌尿生殖系统癌患者为3.0%（3/101），血液系统癌患者为3.7%（59/1590），妇科癌患者为2.7%（3/112），头颈甲状腺和甲状旁腺癌患者为7.8%（26/331），乳腺癌患者为3.5%（7/200），肺癌患者为2.6%（7/271），黑色素瘤患者为3.4%（2/59），肉瘤患者为7.4%（2/27），原发肿瘤不明患者为11.6%（14/121）。
我们的数据显示，原发肿瘤不明的患者脑部/头部病变发生率相对较高。
